{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:13:35Z","timestamp":1783408415749,"version":"3.54.6"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032683","name":"Akita University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032683","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04919-4","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:15:38Z","timestamp":1783404938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis"],"prefix":"10.1007","volume":"96","author":[{"given":"Maiko","family":"Abumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"4919_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ et al (2019) Asciminib in chronic myeloid leukemia after ABL kinaseinhibitor failure. N Engl J Med 381:2315\u20132326","journal-title":"N Engl J Med"},{"key":"4919_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT et al (2024) Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 391:885\u2013898","journal-title":"N Engl J Med"},{"key":"4919_CR3","doi-asserted-by":"crossref","unstructured":"Miura M, Takahashi N (2025) Development and validation of a novel high-performance liquid chromatography assay with ultraviolet detection for determination of asciminib in human plasma. J Chromatogr Sci 63: bmaf056","DOI":"10.1093\/chromsci\/bmaf056"},{"key":"4919_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/00498254.2019.1594449","volume":"50","author":"P Tran","year":"2020","unstructured":"Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B et al (2020) Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica 50:150\u2013169","journal-title":"Xenobiotica"},{"key":"4919_CR5","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/ndt\/16.9.1850","volume":"16","author":"G De Schoenmakere","year":"2001","unstructured":"De Schoenmakere G, Vanholder R, Rottey S, Duym P, Lameire N (2001) Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. Nephrol Dial Transpl 16:1850\u20131855","journal-title":"Nephrol Dial Transpl"},{"key":"4919_CR6","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.5527\/wjn.v14.i1.101917","volume":"14","author":"A Khan","year":"2025","unstructured":"Khan A, Mushtaq M, Movva G, Sohal A, Yang J (2025) Gastrointestinal disease in end-stage renal disease. World J Nephrol 14:101917","journal-title":"World J Nephrol"},{"key":"4919_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cpdd.1019","volume":"11","author":"M Hoch","year":"2022","unstructured":"Hoch M, Zack J, Quinlan M, Huth F, Forte S, Dodd S et al (2022) Pharmacokinetics of asciminib when taken with imatinib or with food. Clin Pharmacol Drug Dev 11:207\u2013219","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4919_CR8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","volume":"63","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF et al (2024) Clinical pharmacology of asciminib: A review. Clin Pharmacokinet 63:1513\u20131528","journal-title":"Clin Pharmacokinet"},{"key":"4919_CR9","unstructured":"FDA (2021) Scemblix. Multidisciplinary review and evaluation: Accessed 22 Apr 2026"},{"key":"4919_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cpt1974165part1761","volume":"16","author":"DT Lowenthal","year":"1974","unstructured":"Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ (1974) Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 16:761\u2013769","journal-title":"Clin Pharmacol Ther"},{"key":"4919_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/00003088-197601050-00004","volume":"1","author":"G Bianchetti","year":"1976","unstructured":"Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, Manfrin M et al (1976) Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1:373\u2013384","journal-title":"Clin Pharmacokinet"},{"key":"4919_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12185-024-03869-y","volume":"121","author":"R Naka","year":"2025","unstructured":"Naka R, Shimomura Y, Miura M, Nagai Y, Kondo T, Ishikawa T (2025) Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis. Int J Hematol 121:272\u2013275","journal-title":"Int J Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04919-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04919-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04919-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:15:47Z","timestamp":1783404947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04919-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4919"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04919-4","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.T. received honoraria (lecture fees), research grants, and consulting fees from Novartis Pharma K.K., and Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Akita University Graduate School of Medicine (Approval No. 2826).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"72"}}